Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462105 | 1.00 | CYP3A4 (0.43) | CYP3A4 | |
| SCHEMBL18018745 | 1.00 | CYP3A4 (0.43) | CYP3A4 | |
| SCHEMBL1881299 | 1.00 | CYP3A4 (0.43) | CYP3A4 | |
| SCHEMBL1537664 | 1.00 | CYP3A4 (0.43) | CYP3A4 | |
| SCHEMBL16276693 | 0.95 | — | — | |
| SCHEMBL19192762 | 0.89 | CYP3A4 (0.37) | CYP3A4 | |
| SCHEMBL12055304 | 0.86 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL12588631 | 0.86 | CYP3A4 (0.35) | CYP3A4 | |
| SCHEMBL14301676 | 0.85 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL8248969 | 0.84 | CFD (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073825-B2 | Methods and intermediates for preparing macrolactams | MERCK SHARP & DOHME LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| US-9073825-B2 | Methods and intermediates for preparing macrolactams | MERCK SHARP & DOHME LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| US-20140243519-A1 | METHODS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | disclosed |
| US-20140243519-A1 | METHODS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | disclosed |
| WO-2013028471-A1 | METHODS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| EP-1910378-B1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | BOEHRINGER INGELHEIM INT (DE) | 2012-06-20 | — | — | EP | disclosed |
| EP-1771453-B1 | HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS | BOEHRINGER INGELHEIM INT (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-8093379-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1797111-B1 | ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7767818-B2 | Hepatitis C inhibitor dipeptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7550559-B2 | Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550559-B2 | Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20080200497-A1 | Hepatitis C Inhibitor Peptide Analogs | BAILEY MURRAY D | 2008-08-21 | — | — | US | disclosed |
| US-20080200497-A1 | Hepatitis C Inhibitor Peptide Analogs | BAILEY MURRAY D | 2008-08-21 | — | — | US | disclosed |
| WO-2008098368-A1 | INHIBITORS OF HEPATITIS C NS3 PROTEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2006026352-A1 | ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | DPP3, CTSC, ANPEP | CYP3A4 1024/4885 |
| US-20140243519-A1 | METHODS AND INTERMEDIATES FOR PREPARING MACROLACTAMS | CYP51A1, RCE1, AADAC | CYP3A4 165/4885 |
| US-20080200497-A1 | Hepatitis C Inhibitor Peptide Analogs | HAVCR2, ZC3HAV1, CTSC | CYP3A4 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.